Alder BioPharma (ALDR) Tops Q2 EPS by 13c

Alder BioPharma (NASDAQ: ALDR) reported Q2 EPS of ($1.48), $0.13 better than the analyst estimate of ($1.61).

CEO and President Dr. Randall Schatzman commented (emphasis Street Insider) "We believe that eptinezumab’s highly competitive and differentiated profile, coupled with the fact that it is the only anti-CGRP migraine treatment administered by infusion in development, will provide a distinct commercial advantage for Alder in the emerging CGRP-directed treatment market. We believe that this would translate to a U.S. market opportunity for eptinezumab infusion therapy, if approved, in the range of approximately $1.5 to $2.0 billion. With our balance sheet enhanced by our recently completed public offering and our disciplined spending plan, we are well-positioned to continue advancing eptinezumab and our goal of transforming the treatment of migraine.”

For earnings history and earnings-related data on Alder BioPharma (ALDR) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c